OBJECTIVE： To study clinical effect of argatroban for progressive stroke patients of different cerebral ischemic ranges. METHODS： A total of 116 progressive stroke patients selected from neurology department of our hospital during Feb. 2015-May 2016 were divided into anterior circulation （ischemia） group （n＝60）， posterior circulation （ischemia） group （n＝50） and lacunar （cerebral infarction） group （n＝6） according to cerebral ischemic ranges. They all received routine treatment combined with argatroban， and given continuous intravenous infusion of argatroban 60 mg/d on the day and 2nd day of disease aggravation， and then continuous intravenous infusion of argatroban  5th day after relieving， 3 h/time， bid， 7 d as a treatment course. NIHSS scores， modified RANKIN （mRS） scores， APTT and ADR were compared among 3 groups. RESULTS： Forteen days after treatment， NIHSS scores and mRS scores of 3 groups were decreased significantly compared to before treatment， with statistical significance （P＜0.05）. There was statistical significance between anterior circulation group and posterior circulation group （P＜0.05）. Two hours after treatment， APTT of 3 groups were prolonged significantly， especially in lacunar group， with statistical significance （P＜0.05）. Forty hours after treatment， APTT of 3 groups were recover to normal， without statistical significance （P＞0.05）. No obvious ADR was found in 3 groups. CONCLUSIONS： Argatroban shows significant therapeutic efficacy for progressive stroke of different ischemic ranges with good safety； especially for the patients with anterior circulation ischemics stroke， the effect is quick and anticoagulant effect is significant.